3Toft-Nielsen MB, Damhoh MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab, 2001,86:3717-3723. 被引量：1
4Gautier JF, Choukem SP, Girard J. Physiology of ineretins ( GIP and GLP-1 )and abnormalities in type 2 diabetes. Diabetes Metab, 2008,34 ( Suppl 2 ) : S65-S72. 被引量：1
5De Block CE, Van Gaal LF. GLP-1 receptor agonists for type 2 diabetes. Lancet, 2009,374:4-6. 被引量：1
6Vaidya HB, Goyal RK. Glucagon like peptides-1 modulators as newer target for diabetes. Curr Drug Targets, 2008,9:911-920. 被引量：1
7Vilsboll T, Krarup T, Deacon CF, et al. Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes, 2001,50:609-613. 被引量：1
8Vilsboll T, Krarup T, Madsbad S, et at. Defective amplification of the late phase insulin response to glucose by GIP in obese Type Ⅱ diabetic patients. Diabetologia, 2002,45 : 1111-1119. 被引量：1
9Russell-Jones D. Molecular, pharmacological and clinical aspects ofliraglutide, a once-daily human GLP-1 analogue. Mol Cell Endocrinol, 2009,297 : 137-140. 被引量：1
10Holst JJ. The Physiology of Glucagon-like Peptide 1. Physiol Rev, 2007,87 : 1409-1439. 被引量：1
